On the basis of classical "Gu-Nucleus-E" triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment.

oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment.

Burning Mouth Syndrome

Oral Mucosa Disease

1:Control group Specific medicines and usage, course of treatment are as follows: oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment.
2.Therapeutic regimen of experimental group On the basis of classical "Gu-Nucleus-E" triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment.

oryzanol + vitamin B2 (riboflavin) + vitamin E

Department of Oral Medicine, the Second Affiliated Hospital, School of Medicine Zhejiang University

Head Yuanshi Dian Therapy in Burning Mouth Syndrome

Head Yuanshi Dian Therapy in the Treatment of Burning Mouth Syndrome: a Randomized Controlled Trial

The basic method is to use a swimming scale about 10 cm long, with 10 scales on one side, and the two ends are "0" and "10" ends respectively. 0 indicates no pain and 10 points represents the most severe pain that is unbearable.

Second Affiliated Hospital, School of Medicine, Zhejiang University

Zhejiang Provincial Hospital of TCM

Stomatological Hospital of Guiyang

1:1 randomized controlled clinical trial were used. Random numbers generated by SPSS21.0 will be placed in sequentially coded, sealed, opaque envelopes. When the qualifications of the subjects were determined by the researchers, the envelopes were opened sequentially and the subjects were assigned to groups. The odd number represented the experimental group and the even number represented the control group.

Each of the three centers has a researcher responsible for the treatment and interpretation of the subjects. The head of the research center trained the researcher to unify the standards. Three researchers were not involved in the evaluation of efficacy. Another researcher was responsible for recording pain and emotional nature and degree score, pain index, pain multi-dimensional characteristics score, depression index, Pittsburgh sleep quality index, Kupperman menopause score, dry mouth subjective symptoms questionnaire, saliva flow, and recording laboratory results, and collecting records. Data, analysis of efficacy, the researchers do not know the specific grouping, in order to minimize the subjective impact of the researchers on the test results.

Study subjects will use betadine saline sinus rinse for period of 6 weeks.

Chronic Rhinosinusitis (Diagnosis)

Povidone Iodine solution 5% (0.5% available iodine) by 3MTM has been specially formulated as a nasal antiseptic. They have shown topical application to be clinically safe, tolerable and to be rapidly bacteriocidal against aerobic gram positive and gram- negative bacteria including methicillin resistant Staphylococcus aureus, methicillin resistant Staphylococcus epidermidis, vancomycin resistant Enterococcus faecium and Enterococcus faecalis (VRE) and yeast (3M study 05-011100,05-011017, 05-011322).

Povidone-Iodine

Budesonide is is provided in nebules (1mg/2cc). Patients will place two nebules of budesonide into the 250mls of saline.

Budesonide

St. Paul's Hospital

Betadine Rinses for Chronic Rhinosinusitis Prospective Cohort Study

The Efficacy of Topical Povidone - Iodine Rinses in the Management of Biofilm-associated Chronic Rhinosinusitis

differences in Modified Lund-Kennedy (MLK) endoscopic score after 6 weeks of using Povidone-iodine (PVP-I) sinus rinses.

disease specific quality of life questionnaire score (SNOT-22) in recalcitrant/recurrent CRS patients

We will publish final outcomes as scientific paper.

Amin Javer

Clinical Professor

St. Paul's Hospital, Canada

Short cervical length equal or less than 20 mm
Singleton pregnant women between 18 -24 weeks with no prior history of preterm deliveries.
18 years or older at the time of enrollment.
Consent to participate in the study
Vaginal progesterone as standard of care plus Arabin pessary

Short cervical length equal or less than 20 mm
Singleton pregnant women between 18 -24 weeks with no prior history of preterm deliveries.
18 years or older at the time of enrollment.
Consent to participate in the study
Vaginal progesterone as standard of care

Focus: Prevent Preterm Delivery

Incidental Short Cervix at Mid-trimester

Insertion of Arabin pessary for the prevention of preterm delivery

Arabin Pessary

University of Illinois at Chicago

Arabin Pessary Combine With Vaginal Progesterone Compare With Vaginal Progesterone Alone to Prevent Preterm Delivery in Singleton Pregnancies

"Comparison of Vaginal Progesterone With Arabin Cervical Pessary and Vaginal Progesterone Alone in the Prevention of Preterm Delivery in Singleton Pregnancies With Incidental Premature Shortening of Cervical Length"

1. To compare the effectiveness of the combination of vaginal progesterone and Arabin pessary in the prevention of preterm delivery prior to 37 weeks compared to vaginal progesterone alone.

Mary Stephenson

Professor of Obstetrics and Gynecology

Randomization between two arms: short cervix with vaginal progesterone and Arabin pessary (study group) versus short cervix with vaginal progesterone alone (control group)

candidiasis/hodepine

Head Yuanshi Dian Therapy in Burning Mouth Syndrome

Betadine Rinses for Chronic Rhinosinusitis Prospective Cohort Study

Arabin Pessary Combine With Vaginal Progesterone Compare With Vaginal Progesterone Alone to Prevent Preterm Delivery in Singleton Pregnancies

Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration

Den mest komplette databasen med medisinske urter støttet av vitenskap